Management of Severe Hyperglycemia with Basal-Bolus Insulin Therapy

Introduction to Insulin Intensification

The American Diabetes Association recommends that patients with A1C ≥8.5% who are symptomatic should be treated with basal insulin, and those with A1C >10% require insulin therapy to prevent metabolic decompensation and achieve rapid glycemic control 1
The American Diabetes Association guidelines state that basal insulin alone is insufficient at an A1C level of 10.1%, and basal-bolus insulin is the appropriate next step 1

The American Diabetes Association explicitly states that sulfonylureas should be discontinued when moving beyond basal insulin to basal-bolus regimens, as they are not synergistic with insulin and significantly increase hypoglycemia risk 2
Continuing sulfonylureas with intensive insulin increases hypoglycemia risk 1.5-3 fold based on ADVANCE, ACCORD, and VADT trial data 3

Start basal insulin at 10 units daily or 0.1-0.2 units/kg/day, increasing by 2-4 units every 3-7 days until fasting glucose reaches 80-130 mg/dL 4
Add prandial insulin starting with 4 units at the largest meal, increasing by 1-2 units or 10-15% twice weekly based on 2-hour postprandial glucose readings 4

Target A1C <7% for most patients, though <8% may be appropriate if hypoglycemia risk is high 1
Check blood glucose before meals and at bedtime to guide insulin adjustments, and recheck A1C in 3 months to assess treatment effectiveness 1

Adding a GLP-1 receptor agonist (instead of pioglitazone) provides A1C reduction of 1-1.5% with weight loss benefits and cardiovascular protection 4

The American Diabetes Association recommends that true long-acting insulins, such as glargine, detemir, and degludec, should be dosed once daily due to their 24+ hour duration of action, as dosing 60 units twice daily can create dangerous insulin stacking with unpredictable peaks 5
A total daily insulin dose of 150 units, consisting of 120 units basal and 30 units bolus, is excessive and suggests either severe insulin resistance or an incorrect dosing strategy that increases hypoglycemia risk without achieving glycemic control, according to the American Association of Clinical Endocrinologists 6, 5

The Endocrine Society recommends consolidating to once-daily long-acting insulin by calculating the total current basal dose and reducing it by 20-30% due to likely insulin stacking, starting with 80-90 units once daily of insulin glargine or degludec 5
If using NPH or regular insulin labeled as "long-acting", the American College of Clinical Endocrinology suggests transitioning to a true basal analog, such as glargine U-100, glargine U-300, or degludec, for more predictable pharmacokinetics 5

The American Diabetes Association recommends continuing metformin 1000mg BID, as it provides complementary glucose-lowering through hepatic glucose suppression and should not be discontinued when intensifying insulin, with a strength of evidence level of A 6